N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor

Abstract

The present invention provides compounds of formula (I), which are antagonists of the 5-HT 6 receptor.

1 . A compound of the formula formula I  
     
       
         
         
             
             
         
       
     
     wherein 
 X is selected from the group consisting of —O—, —NH—,  
 —S—, —SO2—, —CH2—, —CH(F)—, —CH(OH)—, and —C(O)—;  
 R1 is selected from the group consisting of optionally substituted phenyl, optionally substituted naphthyl, optionally substituted 5 to 6 membered monocyclic aromatic heterocycle having one heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur and which 5 to 6 membered monocyclic aromatic heterocycle is optionally benzofused;  
 R2 is selected from the group consisting of hydrogen and C 1 -C 3  alkyl;  
 R3 is selected from the group consisting of hydrogen, fluoro, and methyl;  
 R4 is selected from the group consisting of hydrogen, allyl, C2-C4 alkyl, fluorinated C2-C4 alkyl, optionally substituted phenyl, optionally substituted phenylsulfonyl, optionally substituted benzyl, and optionally substituted 5 to 6 membered monocyclic aromatic heterocycle having one or two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, provided that R 4  is not optionally substituted phenylsulfonyl when X is —SO2—, —CH2—, CH(F)—, —CH(OH)—, or —C(O)—; and pharmaceutically acceptable salts thereof.  
 
   
   
       2 - 56 . (canceled)  
   
   
       57 . A method of treating disorders associated with the 5-HT6 receptor, comprising administering to a patient in need thereof an effective amount of N-(2-(6-Fluoro-1H-indol-3-yl)ethyl)-3-(2,2,3,3-tetrafluoropropoxy)benzylamine.